HCKT vs NVDA

HCKT exhibits a dichotomy between strong operational health and poor market performance, highlighted by a strong Piotroski F-Score of 7/9 but a catastrophic 1-year price decline of 51.5%. While earnings growth is robust (64.6% YoY), this is decoupled from revenue, which is contracting (-3.4% YoY), suggesting profitability is driven by cost-cutting rather than organic growth. The dividend is a significant red flag with a payout ratio of 104.35%, rendering it unsustainable. The stock currently trades near its growth-based intrinsic value of $13.57, though it remains well above its defensive Graham Number of $5.3.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.